Additional file 1 of Lipidomics profiling reveals distinct patterns of plasma sphingolipid alterations in Alzheimer’s disease and vascular dementia

Additional file 1: Supplementary Table S1. Diagnostic criteria of clinical subgroups for this study. Supplementary Table S2. Summary of Neuropsychological Battery and Component Tests. Supplementary Table S3. List of quantifiable lipid species in this study. Supplementary Table S4. Median concentrations of SPs in absence or presence of comorbidity or ApoE4 allele. Supplementary Table S5. SPs fold change and BH-p values in presence versus absence of comorbidity or ApoE4 allele. Supplementary Table S6. Median concentrations (nM) of SPs in NCI, CIND, AD and VaD. Supplementary Table S7. SPs Fold change and BH-p values in CIND, AD, VaD compared to NCI. Supplementary Table S8. Associations of SPs and risk of AD or VaD diagnoses, expressed as odds ratio (OR) and BH-adjusted p-values. Supplementary Table S9. AUC values for individual SPs and selected multimarker panel for AD. Supplementary Table S10. AUC values for individual SPs and selected multimarker panel for VaD. Supplementary Table S11. Variables selected by stepwise backwards regression for AD. Supplementary Table S12. Variables selected by stepwise backwards regression for VaD.